ADC Landscape
Roche / Genentech
HER2 · HER2+ breast (adjuvant & metastatic)
ApprovedAntibody–Drug Conjugates
Target
HER2
Payload
DM1 (emtansine)
Payload class
Maytansinoid
Linker
Non-cleavable (SMCC)
Indication
HER2+ breast (adjuvant & metastatic)
Phase
Approved
Partner
ImmunoGen (tech)
Overview
The first HER2 ADC and proof of the non-cleavable/maytansinoid design. Now largely eclipsed by Enhertu in metastatic disease but a backbone in early breast cancer.
Technology
Roche / Genentech works in Antibody–Drug Conjugates — A guided missile: an antibody that flies a chemo warhead straight to the tumor.
Read the Antibody–Drug Conjugates brief →Related companies
Daiichi Sankyo
HER2
Gilead
TROP2
AstraZeneca / Daiichi
TROP2
Pfizer (Seagen)
CD30
Pfizer (Seagen)
Nectin-4
Pfizer (Seagen)
Tissue Factor
Company website / source ↗ Open the interactive map →
◢ Boom-cycle briefing
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.